Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease
Journal of Medical Ethics 33 (3):169-173 (2007)
AbstractStem cells are likely to be used as an alternate source of biological material for neural transplantation to treat Parkinson’s disease in the not too distant future. Among the several ethical criteria that must be fulfilled before proceeding with clinical research, a favourable benefit to risk ratio must be obtained. The potential benefits to the participant and to society are evaluated relative to the risks in an attempt to offer the participants a reasonable choice. Through examination of preclinical studies transplanting stem cells in animals and the transplantation of fetal tissue in patients with Parkinson’s disease, a current set of potential benefits and risks for neural transplantation of stem cells in clinical research of Parkinson’s disease are derived. The potential benefits to research participants undergoing stem cell transplantation are relief of parkinsonian symptoms and decreasing doses of parkinsonian drugs. Transplantation of stem cells as a treatment for Parkinson’s disease may benefit society by providing knowledge that can be used to help determine better treatments in the future. The risks to research participants undergoing stem cell transplantation include tumour formation, inappropriate stem cell migration, immune rejection of transplanted stem cells, haemorrhage during neurosurgery and postoperative infection. Although some of these risks are general to neurosurgical transplantation and may not be reduced for participants, the potential risk of tumour formation and inappropriate stem cell migration must be minimised before obtaining a favourable potential benefit to risk calculus and to provide participants with a reasonable choice before they enrol in clinical studies
Similar books and articles
Resolving Ethical Issues in Stem Cell Clinical Trials: The Example of Parkinson Disease.Bernard Lo & Lindsay Parham - 2010 - Journal of Law, Medicine and Ethics 38 (2):257-266.
Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells.Ronald K. F. Fung & Ian H. Kerridge - 2013 - Bioethics 27 (2):89-96.
Moral Complicity in Induced Pluripotent Stem Cell Research.Mark T. Brown - 2009 - Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Questions Concerning the Clinical Translation of Cell-Based Interventions Under an Innovation Pathway.Jeremy Sugarman - 2012 - Journal of Law, Medicine and Ethics 40 (4):945-950.
International Society for Stem Cell Research (ISSCR) Guidelines for the Conduct of Human Embryonic Stem Cell Research (December 2006).Bernard Dickens - unknown
Stem Cell Research: An Ethical Evaluation of Policy Options.Nikolaus Knoepffler - 2004 - Kennedy Institute of Ethics Journal 14 (1):55-74.
Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges.Insoo Hyun - 2010 - Journal of Law, Medicine and Ethics 38 (2):277-285.
Systems Bioethics and Stem Cell Biology.Jason Scott Robert, Jane Maienschein & Manfred D. Laubichler - 2006 - Journal of Bioethical Inquiry 3 (1-2):19-31.
Developments in Stem Cell Research and Therapeutic Cloning: Islamic Ethical Positions, a Review.Hossam E. Fadel - 2012 - Bioethics 26 (3):128-135.
Stem Cell Treatments in China: Rethinking the Patient Role in the Global Bio‐Economy.Haidan Chen & Herbert Gottweis - 2013 - Bioethics 27 (4):194-207.
Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
Stemming the Tide of Normalisation: An Expanded Feminist Analysis of the Ethics and Social Impact of Embryonic Stem Cell Research.Shelley Tremain - 2006 - Journal of Bioethical Inquiry 3 (1-2):33-42.
Ethical Challenges in Cell-Based Interventions for Neurological Conditions: Some Lessons To Be Learnt From Clinical Transplantation Trials in Patients with Parkinson's Disease.Elisabeth Hildt - 2009 - American Journal of Bioethics 9 (5):37-38.
Added to PP
Historical graph of downloads
Citations of this work
Ethical Criteria for Human Trials of Stem-Cell-Derived Dopaminergic Neurons in Parkinson's Disease.Samia A. Hurst, Alex Mauron, Shahan Momjian & Pierre R. Burkhard - 2015 - American Journal of Bioethics Neuroscience 6 (1):52-60.
Unintended Changes in Cognition, Mood, and Behavior Arising From Cell-Based Interventions for Neurological Conditions: Ethical Challenges.P. S. Duggan, A. W. Siegel, D. M. Blass, H. Bok, J. T. Coyle, R. Faden, J. Finkel, J. D. Gearhart, H. T. Greely, A. Hillis, A. Hoke, R. Johnson, M. Johnston, J. Kahn, D. Kerr & P. King - 2009 - American Journal of Bioethics 9 (5):31-36.
Rethinking Risk Assessment for Emerging Technology First-in-Human Trials.Anna Genske & Sabrina Engel-Glatter - 2016 - Medicine, Health Care and Philosophy 19 (1):125-139.
Scare-Mongering and the Anticipatory Ethics of Experimental Technologies.Adrian Carter, Perry Bartlett & Wayne Hall - 2009 - American Journal of Bioethics 9 (5):47-48.
Translational Genomics: Seeking a Shared Vision of Benefit.Wylie Burke, Patricia Kuszler, Helene Starks, Suzanne Holland & Nancy Press - 2008 - American Journal of Bioethics 8 (3):54-56.
References found in this work
Placebo Orthodoxy in Clinical Research I: Empirical and Methodological Myths.Benjamin Freedman, Charles Weijer & Kathleen Cranley Glass - 1996 - Journal of Law, Medicine and Ethics 24 (3):243-251.